Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-517

I don't know anything about this stock's history, but as a doctor I find these latest results very unimpressive. Eliminating nasal Staph carriage in ¾ of patients is pretty much useless in a clinical setting (let alone the fact that most got their Staph back in only a few weeks).

Think about it - suppose I am a specialist admitting four patients to hospital for procedures. They are putting their trust in me to do what is best for them. Am I going to give them a treatment that only works for 3 of them but has theoretical benefits to the general population (and leaves me with a major problem to deal with in the other patient), or am I going to use an established treatment that works for all 4, makes my life easier, but MAY not be the best idea for the community in the long run?

Exactly.